Both Seattle and Pieris have been busy on the deal front, and today their lists grew longer as the two pair on developing immuno-oncology treatments.
Syndesi begins life with a $20.9 million infusion, to carry a SV2A modulator through early proof of concept.
Madrigal Pharma is celebrating after its lead drug, MGL-3196, hit the mark in a phase 2 trial in the second of its two target indications: heterozygous…
Nebula will enable people to directly, anonymously sell their data to drug developers using a blockchain-enabled peer-to-peer network.
The 30-startup hub will supersede the JLINX incubator J&J helped to set up at its R&D site in Beerse, Belgium.
Theravance will bring its GI drug through phase 2/3 in Crohn's disease and ulcerative colitis.
The French pharma gained full control of the anti-LAMP1 drug as part of a recent deal but has now removed the asset from its pipeline.
Celltex Therapeutics and Texas A&M Institute for Regenerative Medicine hope to have a stem cell-derived therapy for Alzheimer’s within three years.
Array's combo treatment nearly doubled survival in melanoma patients compared to Roche’s Zelboraf.
The drug offered more relief than placebo to migraine patients, but the size of the effect and cases of elevated liver enzymes leave room for doubts.